Heparin Market Report (2022 to 2030) – Baxter, Pfizer Inc, P. Brown Melsungen AG, GlaxoSmithKline plc, Sanofi and Sandoz

NEWARK, New Castle, USA, Jan. 23, 2023 (Globe Newswire) — According to the report published by Growth Plus Reports, the global heparin market has been estimated $9.1 billion in 2021 It is expected to exceed the rating $12.18 billion by 2030advance in A compound annual growth rate of 3.30% From 2022 to 2030. The report provides detailed analysis of top strategies, drivers, winning opportunities, competitive scenario, fluctuating market trends, market size, statistics, estimations, and key investment pockets.

Download PDF Brochure of Heparin Market Size – Impact of COVID-19 and Global Analysis with Strategic Developments on: https://www.growthplusreports.com/inquiry/request-sample/heparin-market/8074

The global heparin market is mainly driven by the increasing demand for heparin in surgical procedures and the prevalence of cardiovascular diseases. In addition, increasing numbers of major players, emerging diagnostic industry with multiple uses of heparin, and growing awareness about multiple medical uses of heparin are also contributing to the growth of the global heparin market.

Heparin is an anticoagulant prescribed to avoid blood clots and to treat a variety of disorders, including deep vein thrombosis and atrial fibrillation. Heparin is also used to prevent blood clots in people who have certain medical problems or who are undergoing certain surgical treatments that increase the risk of blood clots forming. Because heparin is used to prevent blood clotting in the arteries, it cannot be used to reduce the percentage of clots that have already formed. Heparin is mainly used in angioplasty and angiography to prevent blood clots from forming in catheters.

growth engines

The increasing prevalence of cardiovascular diseases is driving the growth of the global heparin market. In June 2021, the World Health Organization stated that cardiovascular disease is the leading cause of death worldwide, killing approximately 17.9 million people each year. Cardiovascular diseases are a group of diseases of the heart and blood vessels that include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other diseases. Heart attacks and strokes cause more than four in five cardiovascular deaths, with a third of these deaths occurring in people under the age of 70. The most important behavioral risk factors for heart disease and stroke include poor diet, physical inactivity, cigarette use, and problematic alcohol consumption. Individuals may experience the effects of behavioral risk factors such as high blood pressure, high blood sugar, high blood lipids, and being overweight or obese.

Story continues

The global heparin market has been analyzed from five different perspectives – type, source, application, end user, and region

Excerpt from “By Genre”

The global heparin market has been segmented on the basis of type:

Low molecular weight heparin dominates the global heparin market primarily because of its significant therapeutic efficacy, superior bioavailability, prolonged half-life, and ability to be administered subcutaneously. Moreover, the excellent safety and low toxicity of heparin also drives the growth of the segment in the market.

Excerpts from “by source”

The global heparin market has been segmented based on the source into swine and bovine. Porcine dominates the global heparin market due to the high demand for porcine for extraction of low molecular weight heparin and the cheap availability of raw materials. However, due to the limited acceptance of pig-based products among the Muslim and Jewish populations, it is expected that the pig sector market will limit to a certain extent.

Excerpt from “By Application”

The global heparin market has been segmented based on application:

Heat attacks dominate the global heparin market due to the increasing frequency of cardiovascular disorders and the increasing number of heart attacks. Moreover, the significant therapeutic efficacy of heparin in treating cardiovascular diseases adds to the growth of the global heparin market. According to the Centers for Disease Control and Prevention, heart disease is the leading cause of death in the United States. Every 34 seconds, someone in the United States dies of cardiovascular disease. Heart disease claimed more than 697,000 lives in the United States in 2020.

Browse the full report with detailed table of contents at: https://www.growthplusreports.com/report/heparin-market/8074

Excerpts from “By District Division

The global heparin market has been segmented as:

• North Amarica

• Europe

• Asia Pacific

• the rest of the world

North America dominates the global heparin market, followed by the Asia Pacific region. North America’s large share in the global market is attributed to the increasing prevalence of cardiovascular diseases in the region, increasing numbers of hospitals and clinics, and increasing demand for cardiac surgeries. The Asia Pacific region is also expected to show the highest growth rate in the coming years due to the aging population, high prevalence of cardiovascular diseases, and emerging diagnostics industry.

Excerpt from “The Competitive Landscape”

The prominent players operating in the global heparin market are:

• Opocrin SpA

• Baxter

• Pfizer

• Bioiberica SAU

• Fresenius SE & Co. KGaA

• Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Ltd.,

• B.Braun Melsungen AG

• Dr. Reddy’s Laboratories Ltd.

• GlaxoSmithKline Company

• Sanofi

• Sandoz

• LEO Pharma A/S Inc.

• Aspen Holdings

Value propositions related to the report:

• Backed by free analyst hours and expert interviews with every report

• Comprehensive quantitative and qualitative insights at the sector and sub-segment level

• COVID-19 impact trends and perspectives

• Accurate insights at the global/regional/country level

• Deep-rooted insights into market dynamics (drivers, constraints, opportunities) and business environment

• Comprehensive coverage of the competitive landscape

• Winning imperatives

• Comprehensive coverage on “strategic developments” recorded by the leading market players

Customization options:

• Distributor Landscape Assessment

• pricing intelligence

• Evaluate the customer base

• Analysis of initiatives and investment

• “Business Profile” of the main players

Inquire before buying: https://www.growthplusreports.com/inquiry/before-buying/heparin-market/8074

about us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge services company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

The Growth Plus suite of services builds on our core capabilities of secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, groundbreaking solutions that prepare them for future growth and success.

We have been awarded by the prestigious CEO Magazine as the “Most Innovative Healthcare Market Research Firm in 2020.”

CONTACT: Manan Sethi Director, Market Insights Email: enquire@growthplusreports.com Phone no: +1 888 550 5009 Web: https://growthplusreports.com/